EMA Withdrawn: Ipreziv (azilsartan medoxomil) — Takeda Pharma A/S

View source ↗

Summary

The EMA has withdrawn Ipreziv (azilsartan medoxomil) from the European market for hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Ipreziv (azilsartan medoxomil)

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Takeda Pharma A/S. Decision date: 27/10/2014